Biomarcadores moleculares em gliomas malignos: uma análise cienciométrica

Abstract

Malignant gliomas, also known as glioblastoma multiforme (GBM), are highly aggressive tumors with poor prognosis, necessitating improved treatment options and reliable biomarkers to predict therapeutic responses and outcomes. As a direct consequence, the 2021 World Health Organization’s Central Nervous System Tumor Classification underwent a radical overhaul, incorporating several molecular biomarkers. This study investigates key biomarkers in GBM patients through a scientometric review of literature from Scopus and Web of Science databases, covering december 2016 to december 2023 and resulting in 64 selected articles. The analysis highlighted China’s predominance in article production and a strong global emphasis on biomarkers O6-methylguanine-DNA methyltransferase (MGMT) and Isocitrate Dehydrogenase isoform 1 (IDH 1), along with the identification of an increase in molecular studies over the years, in line with the World Health Organization’s glioma classification updates. Given the findings that underscore the importance of MGMT and IDH 1 biomarkers in the context of glioblastomas, and in light of the increasing focus on molecular studies, future prospects warrant a more in-depth investigation into the clinical applicability of these biomarkers. Furthermore, subsequent studies should concentrate on developing targeted therapies that incorporate current molecular insights, with the aim of substantially enhancing patient prognoses and quality of life.